Skip to main content

Advertisement

SpringerLink
Log in

The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The incidence of cholangiocarcinoma has doubled over the last 15 years with a similar rise in mortality, which provides the impetus for standardization of evidence-based care through the establishment of guidelines.

Methods

We compared available guidelines on the clinical management of cholangiocarcinoma in the United States and Europe, which included the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), British Society of Gastroenterology (BSG) and the International Liver Cancer Association (ILCA) guidelines.

Results

There is discordance in the recommendation for biopsy in patients with potentially resectable cholangiocarcinoma and in the recommendation for use of fluorodeoxyglucose positron emission tomography scans. Similarly, the recommendation for preoperative biliary drainage for extrahepatic and perihilar cholangiocarcinoma in the setting of jaundice is inconsistent across all four guidelines. The BILCAP (capecitabine) and ABC-02 trials (gemcitabine with cisplatin) have provided the strongest evidence for systemic therapy in the adjuvant and palliative settings, respectively, but all guidelines have refrained from setting them as standard of care, given heterogeneity in the study cohorts and ABC-02’s negative intention-to-treat results.

Conclusions

Future progress in enhancing survivorship of patients with cholangiocarcinoma would likely entail improvements in diagnostic biomarkers and novel systemic therapies. Based on recent results from studies of targeted therapy, future iterations of the guidelines will likely incorporate molecular profiling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

adapted from McClements S., Khan S.A. (2019) Epidemiology and Pathogenesis of Cholangiocarcinoma. In: Cross T., Palmer D. (eds) Liver Cancers. Springer, Chamy

Fig. 2

References

  1. Patel N, Benipal B. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus. 2019;11(1):e3962.

    PubMed  PubMed Central  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  PubMed  Google Scholar 

  3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353–7.

    Article  CAS  PubMed  Google Scholar 

  4. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48(6):816–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. von Hahn T, Ciesek S, Wegener G, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46(9):1092–8.

    Article  Google Scholar 

  6. Shin HR, Oh JK, Lim MK, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011–6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99(11):895–7.

    Article  PubMed  Google Scholar 

  8. Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848–54.

    Article  PubMed  Google Scholar 

  9. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–84.

    Article  CAS  PubMed  Google Scholar 

  10. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69–76.

    Article  PubMed  PubMed Central  Google Scholar 

  12. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers, Version 4.2019. 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed February 2, 2020.

  13. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–37.

    Article  CAS  PubMed  Google Scholar 

  14. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.

    Article  CAS  PubMed  Google Scholar 

  15. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

    Article  PubMed  Google Scholar 

  16. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.

    Article  PubMed  Google Scholar 

  17. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(1):204–7.

    Article  CAS  PubMed  Google Scholar 

  18. Hultcrantz R, Olsson R, Danielsson A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol. 1999;30(4):669–73.

    Article  CAS  PubMed  Google Scholar 

  19. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530–8.

    Article  CAS  PubMed  Google Scholar 

  20. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.

    Article  PubMed  Google Scholar 

  21. Hamrick-Turner J, Abbitt PL, Ros PR. Intrahepatic cholangiocarcinoma: MR appearance. AJR Am J Roentgenol. 1992;158(1):77–9.

    Article  CAS  PubMed  Google Scholar 

  22. Fan ZM, Yamashita Y, Harada M, et al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. AJR Am J Roentgenol. 1993;161(2):313–7.

    Article  CAS  PubMed  Google Scholar 

  23. Weber A, von Weyhern C, Fend F, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol. 2008;14(7):1097–101.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gonda TA, Glick MP, Sethi A, et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc. 2012;75(1):74–9.

    Article  PubMed  Google Scholar 

  25. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131(4):1064–72.

    Article  PubMed  Google Scholar 

  26. Razumilava N, Gleeson FC, Gores GJ. Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. Am J Gastroenterol. 2015;110(1):200.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Pitman MB, Layfield LJ. Guidelines for pancreaticobiliary cytology from the papanicolaou society of cytopathology: a review. Cancer Cytopathol. 2014;122(6):399–411.

    Article  PubMed  Google Scholar 

  28. Heimbach JK, Sanchez W, Rosen CB, et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011;13(5):356–60.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20(Suppl 1):S49-60.

    Article  PubMed  Google Scholar 

  30. Ferrone CR, Ting DT, Shahid M, et al. The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin rNA in situ hybridization technology. Ann Surg Oncol. 2016;23(1):290–6.

    Article  PubMed  Google Scholar 

  31. Lin F, Shi J, Wang HL, et al. Detection of albumin expression by RNA in situ hybridization is a sensitive and specific method for identification of hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Am J Clin Pathol. 2018;150(1):58–64.

    Article  CAS  PubMed  Google Scholar 

  32. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9.

    Article  CAS  PubMed  Google Scholar 

  33. Goyal L, Govindan A, Sheth RA, et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) Mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015;20(9):1019–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32(25):3091–100.

    Article  CAS  PubMed  Google Scholar 

  35. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029–35.

    Article  CAS  PubMed  Google Scholar 

  36. Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145–51.

    Article  PubMed  Google Scholar 

  37. Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90–7.

    Article  PubMed  Google Scholar 

  38. Kim YJ, Yun M, Lee WJ, et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30(11):1467–72.

    Article  PubMed  Google Scholar 

  39. Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.

    Article  PubMed  Google Scholar 

  40. Rauws EA, Kloek JJ, Gouma DJ, et al. Staging of cholangiocarcinoma: the role of endoscopy. HPB (Oxford). 2008;10(2):110–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gleeson FC, Rajan E, Levy MJ, et al. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2008;67(3):438–43.

    Article  PubMed  Google Scholar 

  42. Ruys AT, Busch OR, Gouma DJ, et al. Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile? Ann Surg Oncol. 2011;18(9):2647–53.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Fong ZV, Alvino DML, Fernandez-Del Castillo C, et al. Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma: a contemporary analysis of 1001 patients. Ann Surg Oncol. 2017;24(11):3203–11.

    Article  PubMed  Google Scholar 

  44. Sell NM, Fong ZV, Del Castillo CF, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 2018;25(4):1009–16.

    Article  PubMed  Google Scholar 

  45. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  PubMed  Google Scholar 

  46. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.

    Article  PubMed  Google Scholar 

  47. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.

    Article  PubMed  Google Scholar 

  48. Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–88.

    Article  CAS  PubMed  Google Scholar 

  49. Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105(7):839–47.

    Article  PubMed  Google Scholar 

  50. Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020.

  51. Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03579771. Accessed July 4, 2020.

  52. Sotiropoulos GC, Bockhorn M, Sgourakis G, et al. R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis. Dig Dis Sci. 2009;54(4):887–94.

    Article  PubMed  Google Scholar 

  53. Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147(12):1107–13.

    Article  PubMed  Google Scholar 

  54. Carpizo DR, D'Angelica M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2009; 18(2):289-305, viii-ix.

  55. Zhang XF, Xue F, Dong DH, et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Ann Surg. 2020.

  56. Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88(11):1463–6.

    Article  CAS  PubMed  Google Scholar 

  57. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16(11):3048–56.

    Article  PubMed  Google Scholar 

  58. Clark CJ, Wood-Wentz CM, Reid-Lombardo KM, et al. Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford). 2011;13(9):612–20.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer. 2011; 117(10):2170-7.

  60. Martin SP, Drake J, Wach MM, et al. Laparoscopic approach to intrahepatic cholangiocarcinoma is associated with an exacerbation of inadequate nodal staging. Ann Surg Oncol. 2019;26(6):1851–7.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Lee DD, Croome KP, Musto KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma. Liver Transpl. 2018;24(5):634–44.

    Article  PubMed  Google Scholar 

  62. Lunsford KE, Court C, Seok Lee Y, et al. Propensity-matched analysis of patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2018;24(10):1384–97.

    Article  PubMed  Google Scholar 

  63. Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337–48.

    Article  PubMed  Google Scholar 

  64. Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma. Available at: https://clinicaltrials.gov/ct2/show/NCT04195503. Accessed July 4, 2020.

  65. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.

    Article  CAS  PubMed  Google Scholar 

  66. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.

    Article  PubMed  Google Scholar 

  67. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III Study. J Clin Oncol. 2019;37(8):658–67.

    Article  CAS  PubMed  Google Scholar 

  68. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202.

    Article  CAS  PubMed  Google Scholar 

  69. Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14(8):514–22.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811–8.

    Article  PubMed  Google Scholar 

  71. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149(5):432–8.

    Article  PubMed  Google Scholar 

  72. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  PubMed  Google Scholar 

  73. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–30.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol. 2020.

  76. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020.

  77. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34(3):219–26.

    Article  CAS  PubMed  Google Scholar 

  79. Hong TS, Wo JY, Yeap BY, et al. Multi-Institutional Phase II Study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460–8.

    Article  CAS  PubMed  Google Scholar 

  80. Schiffman SC, Metzger T, Dubel G, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–8.

    Article  PubMed  Google Scholar 

  81. Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.

    CAS  PubMed  Google Scholar 

  82. Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011;196(2):W205–9.

    Article  PubMed  Google Scholar 

  83. Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86.

    Article  PubMed  Google Scholar 

  84. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.

    Article  CAS  PubMed  Google Scholar 

  85. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.

    Article  PubMed  Google Scholar 

  86. Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–8.

    Article  PubMed  Google Scholar 

  87. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019.

  89. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2019.

  90. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):148–53.

    Article  CAS  PubMed  Google Scholar 

  91. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997; 174(6):605-8; discussion 608-9.

  92. Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg. 1999;134(3):261–6.

    Article  CAS  PubMed  Google Scholar 

  93. De Palma GD, Galloro G, Siciliano S, et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc. 2001;53(6):547–53.

    Article  PubMed  Google Scholar 

  94. Nakeeb A, Pitt HA. The role of preoperative biliary decompression in obstructive jaundice. Hepatogastroenterology. 1995;42(4):332–7.

    CAS  PubMed  Google Scholar 

  95. Inamdar S, Slattery E, Bhalla R, et al. Comparison of adverse events for endoscopic vs percutaneous biliary drainage in the treatment of malignant biliary tract obstruction in an inpatient national cohort. JAMA Oncol. 2016;2(1):112–7.

    Article  PubMed  Google Scholar 

  96. O’Brien S, Bhutiani N, Egger ME, et al. Comparing the efficacy of initial percutaneous transhepatic biliary drainage and endoscopic retrograde cholangiopancreatography with stenting for relief of biliary obstruction in unresectable cholangiocarcinoma. Surg Endosc. 2020;34(3):1186–90.

    Article  CAS  PubMed  Google Scholar 

  97. Moss AC, Morris E, Leyden J, et al. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol. 2007;19(12):1119–24.

    Article  CAS  PubMed  Google Scholar 

  98. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 2006;63(7):986–95.

    Article  PubMed  Google Scholar 

  99. Yeoh KG, Zimmerman MJ, Cunningham JT, et al. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999;49(4 Pt 1):466–71.

    Article  CAS  PubMed  Google Scholar 

  100. Kennedy TJ, Yopp A, Qin Y, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford). 2009;11(5):445–51.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Farges O, Regimbeau JM, Fuks D, et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg. 2013;100(2):274–83.

    Article  CAS  PubMed  Google Scholar 

  102. Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 2012;147(1):26–34.

    Article  PubMed  Google Scholar 

  103. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008;248(2):273–9.

    Article  PubMed  Google Scholar 

  104. Cho MS, Kim SH, Park SW, et al. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg. 2012;16(9):1672–9.

    Article  PubMed  Google Scholar 

  105. Ota T, Araida T, Yamamoto M, et al. Operative outcome and problems of right hepatic lobectomy with pancreatoduodenectomy for advanced carcinoma of the biliary tract. J Hepatobiliary Pancreat Surg. 2007;14(2):155–8.

    Article  PubMed  Google Scholar 

  106. Miwa S, Kobayashi A, Akahane Y, et al. Is major hepatectomy with pancreatoduodenectomy justified for advanced biliary malignancy? J Hepatobiliary Pancreat Surg. 2007;14(2):136–41.

    Article  PubMed  Google Scholar 

  107. Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol. 2011;2(2):94–107.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–40.

    Article  PubMed  Google Scholar 

  109. Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7(12):1023–33.

    Article  CAS  PubMed  Google Scholar 

  110. Fu BS, Zhang T, Li H, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience. Eur Surg Res. 2011;47(4):218–21.

    Article  PubMed  Google Scholar 

  111. Croome KP, Rosen CB, Heimbach JK, et al. Is liver transplantation appropriate for patients with potentially resectable De Novo Hilar Cholangiocarcinoma? J Am Coll Surg. 2015;221(1):130–9.

    Article  PubMed  Google Scholar 

  112. Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 2018;267(5):797–805.

    Article  PubMed  Google Scholar 

  113. Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213(1):21–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Tan EK, Taner T, Heimbach JK, et al. Liver Transplantation for Peri-Hilar Cholangiocarcinoma. J Gastrointest Surg. 2020.

  115. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005; 242(3):451-8; discussion 458-61.

  116. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146(6):683–9.

    Article  PubMed  Google Scholar 

  117. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012; 143(1):88-98 e3; quiz e14.

  118. Moris D, Kostakis ID, Machairas N, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0220527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Mantel HT, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS One. 2016;11(6):e0156127.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. Salgia RJ, Singal AG, Fu S, et al. Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci. 2014;59(5):1048–54.

    Article  PubMed  Google Scholar 

  121. Liver Resection Versus Radio-Chemotherapy-Transplantation for Hilar Cholangiocarcinoma (TRANSPHIL). Available at: https://clinicaltrials.gov/ct2/show/NCT02232932. Accessed March 27, 2020.

  122. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.

    Article  CAS  PubMed  Google Scholar 

  123. McClements S, Khan SA (2019) Epidemiology and pathogenesis of cholangiocarcinoma. In: Cross T, Palmer D. (eds) Liver Cancers. Springer, Cham.

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Zhi Ven Fong MD, MPH, Sarah A. Brownlee MD, Motaz Qadan MD, PhD & Kenneth K. Tanabe MD

Authors
  1. Zhi Ven Fong MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah A. Brownlee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motaz Qadan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth K. Tanabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth K. Tanabe MD.

Ethics declarations

Disclosure

Kenneth Tanabe – Member of Editorial Board, UpToDate.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fong, Z.V., Brownlee, S.A., Qadan, M. et al. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann Surg Oncol 28, 2660–2674 (2021). https://doi.org/10.1245/s10434-021-09671-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09671-y

Search

Navigation